Literature DB >> 18837065

Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides.

Sigrid Espenlaub1, Andreas Wortmann, Tatjana Engler, Stéphanie Corjon, Stefan Kochanek, Florian Kreppel.   

Abstract

BACKGROUND: Chemical capsid modification of adenovirus vectors with synthetic polymers has been shown to aid in overcoming typical barriers for adenovirus vector-mediated gene transfer. Carbohydrate-based polymers for covalent modification of adenovirus vectors have been largely neglected so far. We utilized a reductive amination strategy to generate a novel class of adenovirus-based glycovectors with a mannan derivative.
METHODS: Reductive amination to covalently couple polysaccharides to the capsid surface of adenovirus serotype 5-based vectors was investigated utilizing an oxidized derivative of mannan. After biochemical and physical characterization of mannanylated vectors, their performance was analysed in vitro in cell lines and primary human cells, and in vivo in mice after local and systemic vector injection.
RESULTS: We describe the successful modification of adenovirus vectors with large polysaccharides by reductive amination. The particles were efficiently modified, physically intact and, importantly, detargeted from the natural Coxsackie and adenovirus receptor/integrin pathway in vitro. In addition, they exhibited significantly decreased transduction of muscle after local delivery and of liver after systemic delivery in mice. However, despite the modification of 60% of capsid surface amino groups, mannanylated particles were unable to evade neutralizing anti-Ad5 antibodies.
CONCLUSIONS: Mannanylated vectors are a paradigm for a novel class of glycoviruses modified with large polysaccharides. Vector promiscuity as one of the important hurdles for Ad-mediated gene transfer could be significantly decreased in vivo, whereas mannanylated vectors were unable to escape from anti-adenovirus antibodies. Our studies provide a detailed analysis of mannan-modified Ad vectors and suggest further improvements for this novel class of glycovectors. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837065     DOI: 10.1002/jgm.1262

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  8 in total

Review 1.  Engineering biomaterial systems to enhance viral vector gene delivery.

Authors:  Jae-Hyung Jang; David V Schaffer; Lonnie D Shea
Journal:  Mol Ther       Date:  2011-05-31       Impact factor: 11.454

Review 2.  Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.

Authors:  Franziska Jönsson; Florian Kreppel
Journal:  Virus Genes       Date:  2017-07-28       Impact factor: 2.332

Review 3.  Adenoviral vector immunity: its implications and circumvention strategies.

Authors:  Yadvinder S Ahi; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

Review 4.  Strategies to circumvent humoral immunity to adeno-associated viral vectors.

Authors:  Longping V Tse; Sven Moller-Tank; Aravind Asokan
Journal:  Expert Opin Biol Ther       Date:  2015-06       Impact factor: 4.388

5.  Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.

Authors:  Melissa Bartel; David Schaffer; Hildegard Büning
Journal:  Front Microbiol       Date:  2011-10-04       Impact factor: 5.640

Review 6.  Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.

Authors:  Raquel Yokoda; Bolni M Nagalo; Brent Vernon; Rahmi Oklu; Hassan Albadawi; Thomas T DeLeon; Yumei Zhou; Jan B Egan; Dan G Duda; Mitesh J Borad
Journal:  Oncolytic Virother       Date:  2017-11-08

Review 7.  Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements.

Authors:  Ke-Tao Jin; Wen-Lin Du; Yu-Yao Liu; Huan-Rong Lan; Jing-Xing Si; Xiao-Zhou Mou
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

8.  Chemical Modifications of the Capsid for Redirecting and Improving the Efficacy of Adeno-Associated Virus Vectors.

Authors:  Anh K Lam; Dylan Frabutt; Lei Li; Weidong Xiao
Journal:  Hum Gene Ther       Date:  2021-08-17       Impact factor: 5.695

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.